Navigation Links
InterMune to Release Third Quarter Financial Results on November 5
Date:10/29/2009

BRISBANE, Calif., Oct. 29 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) announced today that it will release third quarter 2009 financial results on Thursday, November 5, 2009 at 4:00 p.m. Eastern time. A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day.

To access the live teleconference, dial 888-799-0528 (U.S.) or 973-200-3372 (international), conference ID# 37626791. To access the webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A replay of the webcast and teleconference will be available approximately three hours after the call. The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 37626791.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which a Phase 3 program in patients with IPF (CAPACITY) has been completed and the compound is currently in the pre-registration stage. The company also has a research program focused on a pirfenidone analog named ITMN-520. The hepatology portfolio includes the HCV protease inhibitor compound RG7227 (ITMN-191) that entered Phase 2b in August of 2009 and a second-generation HCV protease inhibitor research program. For additional information about InterMune and its R&D pipeline,
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis
2. InterMune to Present at Canaccord Adams Conference
3. InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
4. InterMune to Release Second Quarter Financial Results on August 6
5. InterMune to Present at Goldman Sachs Healthcare Conference
6. InterMune Reports First Quarter 2009 Financial Results and Business Highlights
7. InterMune to Release First Quarter Financial Results on April 30
8. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
9. InterMune to Present at Canaccord Adams Hepatitis C Conference
10. InterMune to Present at Citis 4th Annual Biotech Day
11. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Bellingham, Washington, USA, and Cardiff, UK (PRWEB) January 13, ... and photonics technology development leader with more than 20 ... international society for optics and photonics . Hainsey will ... “We are delighted to have Dr. Hainsey join SPIE ...
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 During the ... now known as “The Doctor’s Plague.” In this time period, ... hands. This led, at times, to the death of vulnerable ... today don’t know that they may be unwittingly transmitting herpes ...
(Date:1/14/2014)... January 14, 2014 BioMedomics, Inc. , ... POC diagnostic platforms and novel disease specific POC tests, announced ... financing netting a total of $690,000. The investment is from ... the company. This group of private investors has significant successful ...
(Date:1/14/2014)... Translational Biosciences, a subsidiary of ... trial approval for the treatment of rheumatoid arthritis ... from the Comité Nacional de Bioética de la ... (RA) is an autoimmune disease in which the ...
Breaking Biology Technology:Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3BioMedomics, Inc. Closes $690K Round of Financing 2Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board 2Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board 3
... -- Sinovac Biotech Ltd.,(NYSE Alternext US: SVA), ... today,announced its wholly owned subsidiary, Tangshan Yian ... China,s Ministry of Agriculture to,conduct field trials ... with independent intellectual property rights. With this ...
... 26 MAP,Pharmaceuticals, Inc. (Nasdaq: MAPP ) ... efficacy portion of its initial Phase 3 clinical,trial evaluating ... acute treatment of migraine. , ... potential to be,both fast acting and long-lasting, providing pain ...
... second of its "next-generation" health and longevity products ... cardiovascular healthNEW YORK, Jan. 26 AIM Pharmakon, ... the introduction of the next generation of health ... premium-quality liquid calcium mineral concentrate for bone development ...
Cached Biology Technology:Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine 2Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine 3Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine 4MAP Pharmaceuticals Announces Completion of Enrollment in Phase 3 Clinical Trial of MAP0004 in Patients with Migraine 2MAP Pharmaceuticals Announces Completion of Enrollment in Phase 3 Clinical Trial of MAP0004 in Patients with Migraine 3AIM Pharmakon (API) Announced a New Proprietary Premium-Quality Natural Concentrated Liquid Calcium and Mineral Supplement Now Available Direct to Consumers 2AIM Pharmakon (API) Announced a New Proprietary Premium-Quality Natural Concentrated Liquid Calcium and Mineral Supplement Now Available Direct to Consumers 3AIM Pharmakon (API) Announced a New Proprietary Premium-Quality Natural Concentrated Liquid Calcium and Mineral Supplement Now Available Direct to Consumers 4
(Date:7/9/2014)... ability to switch out one gene for another in ... from science fiction to reality within this decade. As ... promise--the hope of fixing disease-causing genes in humans, for ... scientists have put one of those concerns to rest: ... overall occurrence of mutations in the cells. The new ...
(Date:7/9/2014)... Sexual selection refers to species, selection for traits ... type of natural selection enhances opportunities to mate, the ... Biologists at the University of California, Riverside have now ... of a placenta are linked. Describing the life ... the family Poeciliidae, the researchers found that species with ...
(Date:7/9/2014)... Cancer Genome Atlas (TCGA) Research Network have identified ... lung adenocarcinoma, the most common subtype of lung ... the number of possible therapeutic targets for this ... patients with treatable mutations because many potent cancer ... TCGA is jointly funded and managed by the ...
Breaking Biology News(10 mins):No extra mutations in modified stem cells, study finds 2No extra mutations in modified stem cells, study finds 3Biologists link sexual selection and placenta formation 2Biologists link sexual selection and placenta formation 3Biologists link sexual selection and placenta formation 4Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3
... from the Andes in Colombia to the Atlantic in ... plains of the Llanos and the Guiana shield ... 3rd most important river system on the planet, and one of ... has shown a strong commitment to the achievement of the ...
... citizens negotiated the tensions following the March 4 nationwide ... 2007 vote weighed heavily for many reasons. Among those ... of a new paper in AIDS Reviews , ... do to public health by disrupting treatment and thereby ...
... is an exotic plant originating from the Ukraine and ... Ontario, Canada. It has been found growing successfully in ... edges and understories, parks, road edges and railway embankments. ... large and dense stands that climb over other plants. ...
Cached Biology News:The natural ecosystems in the Colombian Orinoco Basin are in danger 2Political strife undermines HIV treatment 2Political strife undermines HIV treatment 3A European invader outcompetes Canadian plants even outside its usual temperature range 2
One-step, microplate or cuvet, colorimetric, detection range 0.78 ug/dL to 65 ug/dL Zn in serum, plasma, urine, saliva etc. Procedure: 10 min....
Zebrafish Ephrin-B2 Biotinylated Affinity Purified PAb...
... Customer Peptide Synthesis , Containing one Phospho-Amino Acid ... returned to customer conjugation of peptide to KLH protein , ... 102 days/each , Pre-immune bleed x1 /each ... Test bleed (app. 5 ml) x1 /each ...
The Varian 4000 GC/MS system offers three easily switchable ionization configurations: internal ionization (II), external ionization (EI) or hybrid chemical ionization (CI)...
Biology Products: